Abstract
Vedolizumab (VDZ) is a monoclonal antibody approved for the treatment of Crohn’s disease (CD). Despite its efficacy, non-response to VDZ is common in clinical practice with no clear understanding of how it manifests. Here, we characterized the cellular repertoire of responders and non-responders to VDZ during treatment. Peripheral blood mononuclear cells (PBMCs) were isolated from CD patients on VDZ treatment that were either steroid-free responder (N = 4) or non-responder (N = 4). Response was defined as ≥3 drop in Simple Endoscopic Score for Crohn’s Disease (SES-CD) in combination with a ≥50% reduction in C-reactive protein (CRP) and fecal calprotectin and/or a ≥3 point drop in Harvey-Bradshaw Index (HBI). Single-cell repertoires were characterized using single-cell RNA-sequencing (scRNAseq) and mass cytometry by time of flight (CyTOF). Non-responders to VDZ presented more T cells, but fewer myeloid cells. T cells from non-responders presented lower expression of NFкB signaling inhibitors. A lower relative abundance of plasmacytoid dendritic cells (pDCs) was observed among non-responders. Moreover, non-responder-derived classical monocytes presented lower expression of genes involved in wound-healing and cytokine-cytokine receptor signaling. Taken together, non-response to VDZ during treatment is associated with differences in abundance and expression among T and myeloid cells.
Competing Interest Statement
The following authors disclose the following within the past 5 years. ALY received honoraria from Janssen, Johnson & Johnson, DeciBio and was employed by GSK. WJ received speaker fees from Janssen, Johnson & Johnson. GRD received speaker fees from Janssen, Johnson & Johnson. The remaining authors disclose no conflicts.
Funding Statement
This study was funded by the Helmsley Foundation as well as local funds from the Department of Human Genetics and the Tytgat Institute for Liver and Intestinal Research, AmsterdamUMC University of Amsterdam, Amsterdam, Netherlands
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medisch Ethische Toetsingscommissie (METC) of the Amsterdam Universitair Medische Centra, location Academisch Medisch Centrum, gave ethical approval for this work under reference number: NL53989.018.15.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* ALY, IF, and VJ share first authorship. The order was determined based on who designed the study, who aided in the execution of the experimental setup, and who aided in the patient sampling.
↵† WdJ and PH share senior authorship.
Grant support: This work was in part funded by the Helmsley Trust Foundation.
Conflicts of interest The following authors disclose the following within the past 5 years. ALY received honoraria from Janssen, Johnson & Johnson, DeciBio and was employed by GSK. WdJ received ho noraria from Janssen, Johnson & Johnson. GD received speaker fees from Janssen, Johnson & Johnson. The remaining authors disclose no conflicts.
This work has been published as part of a thesis (1) and can be found as a preprint on medRxiv (2).
- Minor textual and stylistic changes across the entire manuscript. - The time between response assessment and start of treatment has been fixed (Figure 1, Methods). - More clinical data has been provided in Table 1.
Data Availability
Raw data produced are available online at the European Genome-phenome Archive. The single-cell RNA-sequencing data can be found under accession number EGAS00001007328. The bulk RNA-sequencing data on classical monocytes can be found under accession number EGAS00001007361. All scripts can be found at https://github.com/ND91/HGPRJ0000008_EPICCD_anti_a4b7_sc
